The aim of this study was to investigate the role of cGMP-dependent protein kinase (PKG) in mediating the anticontractile function of perivascular adipose tissue (PVAT) and whether its activation can rescue PVAT activity which is lost in an experimental model of inflammation.
Introduction
There is accumulating evidence that adipocytes that surround blood vessels play an important modulating role in arterial tone: healthy perivascular adipose tissue (PVAT) is highly metabolically functional and acting in a paracrine manner produces a number of dilators including adiponectin. Healthy PVAT exerts an anticontractile effect on vessels via both endothelium-dependent and endothelium-independent pathways. 1 -3 A number of factors may be released from PVAT that influence arterial function and their bioavailability is embarrassed in obesity and diabetes where the PVAT environment is inflamed and infiltrated by macrophages. 4 -6 Previously, we have demonstrated that adiponectin is one of the key adipokines altered in obesity which influences PVAT function. 4, 7 In this regard, a central role for adiponectin by stimulation of b3-adrenoceptors 8 and acting via BK Ca channels 9 in vascular smooth muscle has been described, but the exact intracellular downstream mechanisms involved are unknown. Previously, we have recreated the inflammatory environment in an ex vivo system by inducing experimental hypoxia. 4 cGMP-dependent protein kinase (PKG) is considered to play a significant role in the relaxation of smooth muscle. 10 Two different PKG isoforms are expressed in mammals, but only cGMP dependent protein kinase I (PKGI) is highly expressed in smooth muscle and can be found in other cells of the vasculature including adipocytes. 11 Induction of PKGI occurs downstream of nitric oxide activation of soluble guanylyl cyclase (sGC) and increases in cGMP, and the resulting relaxation is likely due to a number of phosphorylation events including vasodilatorstimulated phosphoprotein, 12 AMPK, and BK Ca channels. 13, 14 The absence of PKG is associated with hypertension. 15 Furthermore, PKG has been implicated in obesity because recent work has shown that the intake of a high-fat diet is associated with a reduction in adipose tissue PKG expression 11 and so provides a link between obesity and the subsequent loss of the anticontractile capacity of PVAT and development of hypertension. Therefore, we investigated the role of PKG in mediating healthy PVAT function and in response to experimental hypoxia using a series of pharmacological studies on in vitro arterial segments and vessels from a PKG knockout mouse model. We report here that PKG is crucial for the release of relaxing factor(s), including adiponectin, from PVAT and also in the actions of such factors on the vasculature.
Methods
Detailed materials and methods are available in Supplementary material online.
Animals
Procedures were performed in accord with the United Kingdom Animals (Scientific Procedures) Act of 1986 and Institutional Guidelines and conform to the Directive 2010/63/EY of the European Parliament. Male wildtype (PKG +/+ ) and PKGI-deficient (PKG 2/2 ) mice, which were kindly provided by Prof. Hofmann (Munich, Germany) and Prof. Lukowski (Tuebingen, Germany) to Dr ME Werner. B6.129-Adipoq tm1Chan /J adiponectin-deficient mice (adipo 2/2 ) were purchased from The Jackson Laboratory (Maine, USA) and used at 10 weeks. C57Bl/6j mice were purchased from Harlan, UK and used as controls for the adipo 2/2 mice. 9 Mice were killed by cervical dislocation.
Pharmacological assessment of contractility
First-order mesenteric arteries with and without intact PVAT were studied by wire myography 4, 16, 17 (Danish MyoTech, Aarhus, Denmark). Vessels were incubated in physiological salt solution (PSS) at 378C and bubbled with 95% air/5% CO 2 to saturate the vessel bath while maintaining pH 7.4, as previously described.
Wire myography
The contractility of arteries was investigated in PKG 2/2 and PKG +/+ mice under normal oxygen tension and experimentally induced hypoxia (2.5 h 95% N 2 /5% CO 2 ) 16 + atrial natriuretic peptide (ANP) (100 nM) (SigmaAldrich, UK) to increasing doses of norepinephrine (10 29 to 3×10 25 M NE). Endothelial contribution to contractility was assessed by mechanically denuding arteries by passing a wire through the lumen. 16 Pharmacological inhibition of PKG and signalling components of the pathway were used to confirm the role of PKG in mediating the anticontractile capacity of PVAT; the selective, irreversible, haem-site inhibitor of sGC ODQ (10 mM) (Sigma-Aldrich) or the selective, potent inhibitor of type 1 PKG DT-2 (125 nM) (Sigma-Aldrich) 18 were incubated 10 min before initiation and throughout experimental conditions (normal oxygen tension/hypoxia).
Organ bath solution transfer experiments
Solution transfer experiments were employed to study the role of PKG in the release of relaxing factors from PVAT. Arteries with PVAT intact were used as donors, and those devoid of PVAT were used as recipients. Arteries were pre-constricted with 1×10 25 mmol/L norepinephrine and allowed to reach a stable level of constriction. The total bath solution (6 mL) from the recipient's artery was then replaced with that of the donor's artery (6 mL) and change in tension recorded. 4 The role of PKG in the transferrable anticontractile capacity of PVAT was determined using pharmacological tools, ODQ and DT-2, and small artery segments from PKG 2/2 and PKG +/+ animals. Different combinations were used to establish at which point PKG is involved in PVAT-associated relaxation. Furthermore, the response was not due to a shift in sensitivity to norepinephrine, as ED50 values were not significantly different (data not shown). difference in arteries with or without PVAT from PKG 2/2 mice in response to norepinephrine (P ¼ 0.052, n ¼ 13) ( Figure 1C ). 
Histological characterization of PVAT
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PKG activation has protective effects against experimental hypoxia
Induction of experimental hypoxia for 2.5 h caused a loss of the anticontractile effect in PKG +/+ animals, similar to previously published data 16 (P ¼ 0.016, n ¼ 10), but had no effect in PKG 2/2 arteries (P ¼ 0.21, n ¼ 10) (Figure 2) , nor in vessels devoid of PVAT (P ¼ 0.59, n ¼ 10). The presence of ANP during experimental hypoxia was able to prevent the loss of the anticontractile capacity of PVAT in PKG +/+ arteries (P ¼ 0.0093, n ¼ 8) (Figure 2A ) but had no effect in arteries from PKG 2/2 mice (P ¼ 0.11, n ¼ 8) ( Figure 2B ) and was dependent on the presence of PVAT (data not shown).
Adiponectin/PKG interplay mediates normal PVAT function 3.4.1 Adipo 2/2 mice have impaired PVAT function
The contractile response of arteries from adipo 2/2 mice was similar in the presence of PVAT to that of arteries devoid of PVAT, suggesting that the capacity of PVAT was compromised in adipo 2/2 mice (PVAT vs. No PVAT: P ¼ 0.1486, n ¼ 6) ( Figure 3A) . Endothelium integrity was attenuated in adipo 2/2 mice as demonstrated by a reduced ability to relax to acetylcholine (1 × 10 25 mol/L) (P ¼ 0.047, n ¼ 6). As with PKG 2/2 animals, experimental hypoxia had no significant effect on the contractile profile of arteries with or without PVAT from adipo 2/2 mice (PVAT vs. PVAT + hypoxia: P ¼ 0.6507, n ¼ 6) ( Figure 3B ). Incubation with ANP was unable to restore the anticontractile property of PVAT (PVAT + hypoxia vs. PVAT + hypoxia + ANP: P ¼ 0.1538, n ¼ 6); furthermore, inhibition of PKG1a with the selective peptidic inhibitor, DT-2, did not result in any further abrogation of PVAT function in adipo 2/2 mice (P ¼ 0.9618, n ¼ 6) ( Figure 3C ).
Immunohistochemical detection of adiponectin is reduced by hypoxia and increased by ANP
Immunohistochemical detection of adiponectin demonstrated staining around the adipocyte membranes of PVAT in PKG +/+ mice stimulated with norepinephrine (1 × 10 25 mol/L) ( Figure 4A ). The expression of adiponectin as detected by immunohistochemistry was reduced following experimental hypoxia ( Figure 4B ) (normoxia: 7019 + 974.2 vs. hypoxia: 4137.4 + 849.3, P ¼ 0.041), which was prevented by the inclusion of the PKG activator, ANP, during the period of hypoxia ( Figure 4C ) (6413.7 + 507.9, P ¼ 0.049). , respectively, P ¼ 0.188) (see Supplementary material online). Significant differences in the intensity for SOD1 expression were observed, with This effect is prevented in the presence of ANP (n ¼ 10). (B) Experimental hypoxia with or without ANP has no effect on PKG 2/2 arteries (P ¼ NS, n ¼ 10).
Immunohistochemical detection of superoxide dismutase is increased in PKG
PKG and PVAT anticontractile effect the mean area for positive staining in PKG 2/2 and PKG +/+ mice being 7885.7 + 1310.7 mm 3 and 3028.0 + 787.3 mm 3 (P ¼ 0.003) ( Figure 5 ).
Discussion
For the first time, we have demonstrated that PKG is important in mediating PVAT function both in regard to the secretion of adipose-derived relaxing factor(s) and in mediating their vasodilator activity. Because of our previous work which has identified adiponectin as one such adipokine, we focused particularly on the role of PKG in its production and activity. 4, 7 We have demonstrated that the absence of PKG is associated with a loss of the anticontractile capacity of PVAT, increased oxidative stress, and reduced adiponectin expression. Furthermore, hypoxia-induced loss of PVAT function is due to a reduction in adiponectin bioavailability and can be rescued by ANP via its effects on PKG. Solution transfer studies between control arteries and those from the PKG 2/2 mouse demonstrate that PKG is necessary for the release of adipocyte-derived relaxing factor(s) including adiponectin from PVAT and the effects of these factor(s) on the smooth muscle and endothelium ( Figure 6 ). A number of recent studies have demonstrated the presence of nitric oxide signalling components, including PKG, within adipocytes themselves, 19 suggesting that adipocytes may contribute to vascular relaxation in concert with the endothelium, as confirmed by our data in endothelium-denuded wild-type arteries in the presence of PVAT, where there is a significant reduction of the anticontractile effect in response to adrenergic stimulation. These data support our previous findings, where NOS inhibition inhibits PVAT function in human gluteal and mouse mesenteric arteries, 4,9 as well as a role for endothelium-derived NOS in the PVAT effect observed in the rat aorta. 3 Solution transfer studies from NE-pre-constricted donor (PVAT) arteries incubated with the PKG1a-selective inhibitor DT-2, 18 to recipient (no PVAT) arteries pre-constricted with NE alone, were associated with a reduction in the change of tension. This effect did not occur when ODQ was used in donor arteries, suggesting that the specific inhibition of PKG is important in the PVAT-derived effect as opposed to simply the NO signalling pathway. Accumulating evidence indicates that stimulated adipocytes are able to produce nitric oxide. 20 -22 Furthermore, hypoxia has been demonstrated to attenuate cGMP effects in vascular smooth muscle cells 23, 24 and has been shown to change the redox regulation of sGC and downstream vascular responses 25 ; therefore, the presence of PKG in the adipocyte is significant, particularly in relation to the anticontractile capacity of PVAT. Furthermore, data from our laboratory show that BK Ca , a known phosphorylation target for PKG, mediates the PVAT effect; indeed, the hyperpolarization associated with adiponectin is inhibited by BK Ca blockade.
The finding that PKG was involved in mediating the downstream effects of secreted adipokine(s) supports previous studies: NO has been implicated in the vascular response of a number of key adipokines including adiponectin, 26, 27 leptin (reviewed in Joffin et al.
28
), omentin, 29 and resistin 30 ; PKG plays a key role in the NO signalling pathway (reviewed in Francis et al. 31 ), therefore, its absence is likely to disrupt the propagation of endothelium-mediated adipokine induced relaxation. However, taken together our data serve to highlight the importance that PKG inhibition has on normal vascular reactivity. Interestingly, eNOS, known to work upstream of PKG, is involved in the production of adiponectin in adipose tissue through its role in mediating mitochondrial function. 32 We tested whether PKG has any significance in vascular contractility in an experimental model of oxidative stress by induction of experimental hypoxia. 16 Our data show a loss of PVAT activity in PKG +/+ mice, however, hypoxia had no significant effect on arteries from PKG
mice. This is due to increased levels of oxidative stress within the adipose environment, as oxidative stress has been associated previously with impaired PKG activation in response to cGMP. 33 Interestingly, if arteries were incubated with ANP, a known activator of PKG, 31 during the period of experimental hypoxia, there is a significantly reduced loss of PVAT function. It may be that ANP affects other molecules which may impact on the relaxation of the smooth muscle, for example, through cross-talk between cGMP and cAMP pathways 34 ; however, the absence of any beneficial effects in the PKG 2/2 mouse arteries and in the presence of PKG1a inhibitor DT-2 implicates PKG in mediating the protective effects of ANP in this experimental model. Treatment of human primary adipocytes with ANP has been shown previously to increase the secretion and expression of adiponectin, 35 one of the most abundant adipokines. Furthermore, incubation of human adipocytes with a PKG inhibitor reduces adiponectin secretion 36 ; therefore, we wished to determine whether the loss of PVAT function in PKG 2/2 mice was associated with impaired adiponectin bioavailability, which our previous studies have implicated as a key adipokine in the anticontractile capacity of PVAT. Expression of adiponectin was reduced in the adipose tissue of PKG 2/2 mice as determined by immunohistochemical detection of adiponectin, confirming our earlier findings that PKG plays a role in the secretion of adipokine(s) responsible for PVAT function, which we have identified to be adiponectin. Using an adiponectin 2/2 mouse, we confirmed a loss of PVAT function 9 and an impaired endothelial integrity. We believed that the loss of PVAT function was lost in these mice due to the lack of adiponectin and subsequent inability to activate NO, and that activation of PKG, through increased cGMP levels, would result in the restoration of signalling pathways downstream of adiponectin; however, when ANP was incubated with arteries from adiponectin 2/2 mice surprisingly, there was no restorative effect of the PKG signalling pathway and therefore no reestablishment of PVAT anticontractile function. Reviewing the available literature suggests that adiponectin 2/2 mice have a dysregulated NO signalling pathway and that the expression of the components of the pathway is reduced. 37 -39 This would support data from obese subjects in which adiponectin levels are reduced in obese subjects. 40, 41 However, the authors acknowledge that it is likely other adipokines and will be altered in the absence of PKG. Interestingly, recent data have shown an inverse relationship between PKG expression in mice and high-fat diet, furthermore, animals overexpressing PKG were protected from the detrimental effects of obesity induced by high-fat diet. 11 Owing to the impaired gastrointestinal peristalsis associated with the PKG 2/2 mouse, 42 it is difficult to investigate the importance of PKGI in the obese state; although a targeted knockout model would be perhaps useful to facilitate these investigations, our results clearly demonstrate that the expression of PKG goes beyond a single cell type of the vasculature. However, we accept it is necessary to investigate PKG signalling in the obese state to understand its importance in obesity. Ultimately, the important finding of this study is that PKG plays a key role in regulating normal PVAT function and that PKG is necessary upstream of adiponectin expression and downstream of adiponectin Figure 6 PKG mediates adiponectin bioavailability. The figure presents a proposed pathway for adiponectin release mediated by PKG1 signalling and how it is influenced by hypoxia. ANP-activated PKG1 may modulate the release of adiponectin by influencing mitochondrial function an effect inhibited by a PKG1a-selective inhibitor (D) DT-2. Secreted adiponectin from the adipocyte subsequently activates adiponectin receptors (AdR) on the smooth muscle leading to downstream signalling events including AMPK activation, the phosphorylation of eNOS and ensuing nitric oxide (NO) signalling and endothelium-dependent relaxation. Activated PKG1 can then feed back to the mitochondrion to regulate adiponectin secretion and/or NO release at the endothelial level may stimulate soluble guanylate cyclase (sGC) in the adipocyte, which can be inhibited by 1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one (ODQ). Hypoxia can inhibit eNOS and also changes the redox regulation of sGC and thereby influencing downstream vascular responses.
release. Further investigations are required in understanding the significance of these findings in disease states such as diabetes and hypertension.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
